COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

被引：0
|
作者：
Chouaid, C. [1 ]
Bensimon, L. [2 ]
Millier, A. [3 ]
Clay, E. [3 ]
Insinga, R. [4 ]
Arunachalam, A. [4 ]
Khandelwal, A. [5 ]
Bachelot, Levy L. [2 ]
Levy, P. [6 ]
机构：
[1] Creteil Univ Hosp, Dept Chest Med, Creteil, France
[2] MSD France, Courbevoie 92, France
[3] Creat Ceut, Paris 75, France
[4] Merck & Co Inc, N Wales, PA USA
[5] Complete HEOR Solut, Gurgaon, India
[6] Univ Paris 09, PSL Res Univ, LEDA LEGOS, Paris, France
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN116
引用
收藏
页码：S458 / S458
页数：1
相关论文
共 50 条
  • [41] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [42] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [43] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States
    Berling, M.
    Chaudhary, M. A.
    Yuan, Y.
    Varol, N.
    Dale, P.
    Testa, E.
    Klint, J.
    Lee, A.
    Lubinga, S. J.
    Penrod, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S16
  • [44] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS NIVOLUMAB AS THE FIRST-LINE TREATMENT FOR ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER IN UNITED KINGDOM
    Verma, J.
    Verma, D.
    Maria, A.
    VALUE IN HEALTH, 2020, 23 : S41 - S41
  • [45] COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
    Salcedo, E.
    Freire, V
    Cabezas, M.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [46] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [47] Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer
    Noor, Zorawar S.
    Goldman, Jonathan W.
    Lawler, William E.
    Telivala, Bijoy
    Braiteh, Fadi
    DiCarlo, Brian A.
    Kennedy, Kathleen
    Adams, Brad
    Wang, Xiaoyan
    Jones, Benjamin
    Slamon, Dennis J.
    Garon, Edward B.
    LUNG CANCER, 2019, 135 : 104 - 109
  • [48] EFFICIENCY OF CISPLATIN, PEMETREXED, AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR JAPANESE ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Shiraishi, Yoshimasa
    Hirai, Humihiko
    Yamaguchi, Masafumi
    Morodomi, Yosuke
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Toyokawa, Gouji
    Takenaka, Tomoyoshi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
  • [49] An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer
    Afzal, Muhammad Zubair
    Dragnev, Konstantin H.
    Shirai, Keisuke
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [50] PEMETREXED AS FIRST-LINE TREATMENT IN COMBINATION WITH EARLY RADIOTHERAPY IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE ANALYSIS
    Cai, Xuwei
    Zhang, Qin
    Yu, Wen
    Liu, Qi
    Fan, Min
    Feng, Wen
    Zhao, Weixin
    Fu, Xiaolong
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S554 - S554
12345